Last Posted: Mar 06, 2020
- Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
JNCI, March 2020 - The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel Lisanne F et al. Nature communications 2019 10(1) 5251 - Clinical implications of mismatch repair deficiency in prostate cancer.
Sedhom Ramy et al. Future oncology (London, England) 2019 Jul 15(20) 2395-2411 - Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.
Jarrard William E et al. PloS one 2019 14(6) e0218950 - Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones Jose et al. The Prostate 2020 Feb - Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke Julia S et al. International journal of cancer 2020 146(7) 2036-2046 - Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.
Lotan Tamara L et al. The American journal of surgical pathology 2020 Feb - HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
JAMA Oncology, February 13, 2020 - Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.
González-Billalabeitia Enrique et al. Prostate cancer and prostatic diseases 2019 22(2) 195-205 - The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.
Fredsøe Jacob et al. PLoS medicine 2020 Feb 17(2) e1003033
.png)
No hay comentarios:
Publicar un comentario